Shanghai Rightongene Biotechnology Co., Ltd.

SHSE:688217 Stock Report

Market Cap: CN¥1.2b

Shanghai Rightongene Biotechnology Past Earnings Performance

Past criteria checks 0/6

Shanghai Rightongene Biotechnology's earnings have been declining at an average annual rate of -32.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 1.4% per year.

Key information

-32.2%

Earnings growth rate

-38.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate1.4%
Return on equity-1.5%
Net Margin-2.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Apr 23
Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Recent updates

Shanghai Rightongene Biotechnology Co., Ltd.'s (SHSE:688217) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Oct 18
Shanghai Rightongene Biotechnology Co., Ltd.'s (SHSE:688217) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Jul 23
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Apr 23
Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Revenue & Expenses Breakdown

How Shanghai Rightongene Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688217 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24249-513466
30 Jun 24265113973
31 Mar 24266713772
31 Dec 23258812670
30 Sep 233512313266
30 Jun 233793512465
31 Mar 234334412159
31 Dec 224244011964
30 Sep 223544111563
30 Jun 223284411266
31 Mar 222742911775
31 Dec 212914711669
30 Sep 212895310877
30 Jun 212855010470
31 Mar 21307539770
31 Dec 20285399174
31 Dec 192553610667
31 Dec 18224159053

Quality Earnings: 688217 is currently unprofitable.

Growing Profit Margin: 688217 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688217 is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.

Accelerating Growth: Unable to compare 688217's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688217 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 688217 has a negative Return on Equity (-1.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies